Attivare Therapeutics Secures $6.6 Million Gates Foundation Grant for Next-Generation Malaria Vaccine
核心洞察
Attivare Therapeutics (搜索) received a $6.6 million grant from the Gates Foundation (搜索) to advance a long-lasting malaria (搜索) vaccine using their proprietary ATTimmune (搜索) bioscaffold platform.
The ATTimmune (搜索) system utilizes mesoporous silica rods that form 3D immunomodulatory microenvironments, enabling sustained release of vaccine components and potentially extending immunity duration.
The project targets affordable, deployable malaria (搜索) vaccine solutions for low- and middle-income countries where cold-chain infrastructure limitations impede vaccine coverage.
Attivare Therapeutics (搜索) has secured a $6.6 million grant from the Gates Foundation (搜索) to develop a next-generation malaria (搜索) vaccine that could transform global health outcomes in underserved populations. The funding will advance the company's proprietary ATTimmune (搜索) bioscaffold platform, designed to create long-lasting vaccines that address critical infrastructure challenges in low- and middle-income countries.
Revolutionary Bioscaffold Technology
The ATTimmune (搜索) system represents a significant advancement in vaccine delivery technology, utilizing mesoporous silica rods (MSRs) licensed from Dr. Dave Mooney of Harvard's Wyss Institute. These MSR bioscaffolds assemble in vivo, forming a 3D immunomodulatory microenvironment that sustains release of vaccine components while actively recruiting, modulating, and activating immune cells.
"By enabling precise, sustained release of antigens and adjuvants, we aim to significantly extend the duration of vaccine-driven immunity, minimize the required dose and booster frequency, and maximize access for underserved populations," said Dr. David Sherris, President and CEO of Attivare Therapeutics (搜索).
According to Dr. Mooney, "The MSR technology has shown promising results across cancer (搜索), autoimmunity, and infectious disease, including a clinical-stage therapeutic cancer vaccine. It enables targeted delivery, synergistic integration of molecules, and the fine-tuned orchestration of immune responses."
Addressing Global Health Infrastructure Challenges
The project specifically targets challenges faced in low- and middle-income countries, where limited cold-chain infrastructure often impedes vaccine outreach and coverage. The ATTimmune (搜索) platform's inherent biocompatibility and adaptability facilitates the release of diverse immunomodulatory agents with unparalleled control over dose and timing.
"ATTimmune (搜索)'s inherent biocompatibility and adaptability facilitates the release of diverse immunomodulatory agents with unparalleled control over dose and timing, an approach well suited for customizing vaccines against evolving global threats such as malaria (搜索)," Dr. Sherris explained.
Clinical Development and Malaria Impact
The company's clinical proof-of-concept studies will examine the potential for dramatically increasing malaria (搜索) vaccine durability by leveraging controlled slow-release delivery, with data indicating the potential for more potent, longer-lasting, and broader protection.
Malaria (搜索) remains among the most devastating infectious diseases globally, disproportionately affecting children in Africa and causing preventable deaths and suffering. Long-lasting, accessible vaccines are considered a pivotal strategy for malaria eradication.
Platform Versatility
Founded by a team from Harvard's Wyss Institute, Attivare Therapeutics (搜索) has developed the ATTimmune (搜索) platform as a versatile technology capable of recruiting, reprogramming, and releasing target immune cells. The platform can be customized with various immunomodulators to effectively reprogram the immune environment, offering unprecedented 3D spatiotemporal control of bioactive components for both oncology and infectious disease applications.